1 |
King, H., Aubert, R. E. and Herman, W. H. : Global burden of diabetes (1998), 1995-2025. prevalence, numerical estimates, and projections. Diabetes Care 21, 1414 (1998).
|
2 |
Rotella, D. P. : Approaches for the control of type 2 diabetes. Journal of Medicinal Chemistry 47, 4111 (2004).
|
3 |
UK Prospective Diabetes Study (UKPDS) Group : Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837 (1998).
|
4 |
American Diabetes Association : Standards of medical care in diabetes 2008. Diabetes Car. 31 S12 (2008).
|
5 |
Nathan, D. M., Buse, J. B. and Davidson, M. B. : Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consesus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29, 1963 (2006).
|
6 |
Karasik, A., Aschner, P. and Katzeff, H. : Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Current Medical Research and Opinion 24, 489 (2008).
|
7 |
Ahren, B. : Vildagliptin: novel pharmacological approach to treat type 2 diabetes. Therapy 5, 79 (2008).
|
8 |
Deacon, C. F. and Holst, J. : Dipeptidyl peptidase-4 inhibitors: a promising new therapeutic approach for the management type 2 diabetes. International Journal of Biochemistry Cell Biology 38, 831 (2006).
|
9 |
Deacon, C. F., Johnsen, A. H. and Holst, J. J. : Degradation of glucagon- like peptide-1 by human plasma in vitro yields an N terminally truncated peptide that is a major endogenous metabolite in vivo. Journal of Clinical Endocrinology & Metabolism 80, 952 (1995).
|
10 |
National Institute for Health and Clinical Excellence NICE : Type 2 diabetes: newer agents (2009).
|
11 |
Hanefeld, M., Herman, G. A. and Wu, M. : Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Current Medical Research and Opinion 23, 1329 (2007).
|
12 |
Scott, R., Wu, L. and Sanchez, M. : Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. International Journal of Clinical Practice 61, 171 (2007).
|
13 |
Aschner, P., Kipnes, M. S. and Lunceford, J. K. : Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29, 2632 (2006).
|
14 |
Pratley, R. E., Jauffret-Kamel, S. and Galbreath, E. : Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Hormone and Metabolic Research 387, 423 (2006).
|
15 |
Pi-Sunyer, F. X. and Schweizer, A. Mills : Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Research and Clinical Practice 76, 132 (2007).
|
16 |
Mohan, V., Yang. W. and Son, H. Y. : Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Research Clinical Practice 83, 106 (2009).
|
17 |
Dejager, S., Razac, S. and Foley, J. E. : Vildagliptin in drug-naive patients with type 2 diabetes; A 24 double-blind, randomized, placebo-controlled, multiple-dose study. Hormone and Metabolic Research 39, 218 (2007).
|
18 |
Micromedex Healthcare Series: http;//www.micromedex.com.
|
19 |
Charles, F. L., Lora, L. A. and Morton, P. G. : Drug information Handbook 15th edition, Lexi-comp; pp. 829-832, pp. 1010-1013 (2007).
|
20 |
Richter, B., Bandeira-Echtler, E., Bergerhoff, K. and Lerch, C. L. : DPP-4 inhibitors for type 2 diabetes mellitus. Cochrane Database System Review, CD006789 (2008).
|
21 |
Nakanishi, S., Okubo, M., Yoneda, M., Jitsuiki, K., Yamane, K. and Kohno, N. : Comparison between Japanese-American living in Hawaii and Los Angeles and native Japaneses: the impact of lifestyle westernization on diabetes mellitus. Biomedicine Pharmacotherapy 58, 571 (2004).
|
22 |
Petersen, P. H., Jorgensen, L. G. and Brandslund, I. : De Fine Olivarius N, Stahl M, Consequences of bias and imprecision in measurements of glucose and HbA1c for the diagnosis and prognosis of diabetes mellitus. Scand J. Clin. Lab. Invest. Suppl. 240, 51 (2005).
|
23 |
Sacks, D. B., Bruns, D. E., Goldstein, D. E., Maclaren, N. K., Mcdonald, J. M. and Parrott, M. : Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clinical Chemistry 48, 436 (2002).
|
24 |
Sherifali, D., Nerenberg, K., Pullenayegum, E., Cheng, J. E. and Gestein, H. C. : The effect of oral antidiabetic agents on A1c levels. A systematic review and meta-analysis. Diabetes Care 33, 1859 (2010).
|
25 |
Nauck, M. A., Meininger, G. and Sheng, D. : Efficacy and safety of DPP-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind study. Diabetes Obesity & Metabolism 9, 194 (2010).
|
26 |
Monami, M., Iacomelli, I., Marchionni, N. and Mannucci, E. : Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A metaanalysis of randomized clinical trials. Nutrition, Metabolism and Cardiovascular Diseases 20, 224 (2010).
|